Carbapenem-Resistant *Enterobacteriaceae* (CRE) Report Form

Philadelphia Department of Public Health Division of Disease Control



1101 Market St.,12th Floor Philadelphia, PA 19107 Telephone: (215) 685-6748

Fax: (215) 238-6947 Form available at hip.phila.gov

PATIENT DEMOGRAPHIC INFORMATION					
PATIENT'S NAME (LAST, FIRST)			D.O.B.	AGE (years)	SEX
					☐ Male ☐ Female ☐ Other
RACE African-American White Asian Pacific Islander Native-American Unknown Other HISPANIC Yes No UNK					
CURRENT ADDRESS					
FACILITY NAME, if r	esiding in a healthcare/a	ssisted living facility	WAS FACILITY NOTIFIED ☐ Yes ☐ No ☐ Unknown PART OF OUTBREAK/CLUSTER ☐ Yes ☐ No ☐ Unknown		
CLINICAL DATA					
HOSPITALIZED ☐ Yes ☐ No	HOSPITAL NAME	ADMIT DATE	DISCHARGE DATE	Fatal ☐ Yes ☐ N	e Care Unit Yes No UNK o Unknown //
REASON FOR TESTING Screening/Surveillance Signs/Symptoms of Infection SIGNS/SYMPTOMS ONSET DATE, if infection DATE OF FIRST POSITIVE:/					
INFECTION(S) ASSOCIATED WITH CULTURE(S) (Check all that apply) None Blood Respiratory Tract Infection Urinary Tract Infection (UTI) Organ Space/Abscess Skin/Soft Tissue Infection or Wound					
UNDERLYING MEDICAL CONDITIONS (Check all that apply or attach problems list or pertinent sections of medical records) Chronic Heart/Cardiovascular Disease Kidney Disease; Dialysis in Past Year Wound(s), specify: Other, specify: Other, specify: None Unknown					
RISK FACTORS					
IF AVAILABLE, HISTORY OF HEALTHCARE STAYS IN THE UNITED STATES IN THE PREVIOUS YEAR (List where the patient was transferred from first) Facility: Admission/Discharge Dates:					
Facility:					
Facility: Admission/Discharge Dates:/					
HISTORY OF INTERNATIONAL TRAVEL and/or MEDICAL CARE ABROAD IN PREVIOUS YEAR (Check all that apply)					
☐ International Travel ☐ Medical Care Abroad ☐ No ☐ Unknown Dates of travel:/					
SURGERY/PROCEDURE INVOLVING A SCOPING DEVICE IN THE PAST YEAR?					
CURRENT INDWELLING / INVASIVE DEVICE(S)?					
LABORATORY (Please attach culture and sensitivity results and any other applicable test results available)					
SPECIMEN COLLECTION DATE:/ RESULT DATE:/ GENUS and SPECIES:					
SPECIMEN TYPE (C☐Blood ☐	Check all that apply) ☐ Urine	RESISTANT/INTERMEDIATE TO: (Check all that apply)	CARBAPENEMASE PRODU		APENEMASE MECHANISMS C □ NDM □ VIM □ IMP
□ Rectal [☐ Wound	□ Doripenem□ Ertapenem	Test Performed: ☐ Modified Hodge Test	□ох	A-48
□CSF [☐ Sputum	☐ Imipenem	☐ Metallo-β-lactamase Tes		erformed:
□Abscess	☐ Meropenem ☐ Pandrug-Resistant (PDR)		☐ CIM ☐ mCIM		CR
Other, specify:			☐ Carba-NP		
REPORTER INFORMATION					
REPORT DATE	EPORT DATE REPORTER NAME		FACILITY NAME		REPORTER PHONE # & EMAIL
, ,	Role: □DO/M	D □ICP □ PA/NP □RN □ Other:			

PLEASE FAX REPORT TO (215) 238-6947 UPON COMPLETION. RETAIN CRE ISOLATE FOR ONE MONTH

Reporting Guidelines for Carbapenem-resistant Enterobacteriaceae (CRE)

Report all cases of CRE.

Report cases that were identified from diagnostic testing as well as surveillance/screening testing.

A case of CRE is defined as a culture yielding a bacterium in the family *Enterobacteriaceae* (e.g. *Klebsiella*, *Enterobacter*, *Escherichia coli*, *Proteus*, *Serratia*, etc.):

- that tests resistant to at least one carbapenem antibiotic (minimum inhibitory concentrations of ≥ 4 mcg/ml for meropenem, imipenem, and doripenem OR ≥ 2 mcg/ml for ertapenem); or
- 2. that is documented to produce a carbapenemase by means of a laboratory test. Tests shall include but not be limited to, MicroScan, E-test, disk diffusion test, Modified Hodge Test (MHT), Metallo-β-lactamase test, Carba NP, Carbapenem Inactivation Method (CIM), Modified CIM (mCIM), polymerase-chain reaction (PCR), and Gene Xpert CarbaR.

All positive test results should be reported to the Philadelphia Department of Public Health (PDPH) **within 5 days**, with the exception of CRE clusters/outbreaks, which should be reported, via phone, <u>within 24 hours</u>. A CRE Case Report Form should be filled out and faxed to PDPH at (215) 238-6947. Cases may be reported to PDPH via phone at (215) 685-6748.

Isolates should be retained for one month. PDPH will follow up to coordinate further testing as needed.